Scienture Holdings, Inc. - Common Stock SCNX 深 沪
等待开盘 10-02 09:30:00 美东时间
0.8737
+0.024
+2.85%
华盛通- 最 高0.8741
- 今 开0.8477
- 成交量 40.07万股
- 最 低 0.8301
- 昨 收 0.8495
- 总市值 1145.98万
- 52周最高 9.55
- 市盈率 静 --
- 换手率 3.05%
- 52周最低 0.69
- 委 比 -91.50%
- 总股本 1311.64万
- 历史最高 164.50
- 量 比 4.00
- 振 幅 5.18%
- 历史最低 -5.81
- 每 手 1
- 风险率 2.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare institutions and plans to expand further.
10-01 20:46
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
SCIENTURE Holdings announced the signing of GPO agreements for Arbli™ (losartan potassium) Oral Suspension, granting access to over 2,500 healthcare institutions and potentially penetrating 20% of the U.S. institutional market. Arbli™, the first FDA-approved ready-to-use liquid losartan, addresses an unmet need with convenience and accuracy, targeting hypertension, stroke risk reduction, and diabetic nephropathy. With a $256M U.S. losartan market...
10-01 13:00
Scienture Holdings Enters Equity Distribution Agreement
Scienture Holdings ( ($SCNX) ) has provided an announcement. On September 19, 2...
09-24 05:31
EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market
Scienture's Arbli, the first ready-to-use liquid losartan, gains formulary access with coverage for over 100 million lives and discussions for broader access.
09-16 19:45
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
Arbli™ is the first and only FDA-approved, ready-to-use liquid losartan oral suspension, offering a convenient and effective alternative for patients. It received significant commercial support with a rebate agreement covering over 100 million lives, enhancing accessibility.
09-16 12:05
Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
Scienture Holdings, Inc. (NASDAQ: SCNX) has entered into a securities purchase agreement with institutional investors for a registered direct offering of 3,225,000 common shares at $1.20 per share, raising approximately $3.9 million. The offering is expected to close on August 15, 2025, subject to customary conditions. Maxim Group LLC is acting as the sole placement agent. The offering is made under a shelf registration statement on Form S-3 (Fil...
08-14 13:00
Scienture Launches Arbli, First FDA-Approved Ready-To-Use Liquid Losartan
SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing,
08-13 20:17
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
SCIENTURE HOLDINGS, INC. announced the shipment of Arbli<sup>™</sup> (losartan potassium) Oral Suspension, 10 mg/mL, a first-of-its-kind FDA-approved ready-to-use liquid losartan formulation for treating hypertension, reducing stroke risk, and managing diabetic nephropathy.arbli<sup>™</sup> eliminates the need for compounding and offers a convenient, safe option for patients. The company has received its first order, marking a major milestone tow...
08-13 12:05
Scienture Holdings Q2 EPS $(0.48) Up From $(1.16) YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.48) per share. This is a 58.62 percent increase over losses of $(1.16) per share from the same period last year.
08-12 21:32
